Article

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

2020-11-05

Abstract excerpt

Introduction: Tyrosine kinase inhibitors (TKIs) are an effective therapy for pts with CML. However, resistance to treatment driven by point mutations in the ABL kinase domain, particularly the T315I mutation, represents a clinical challenge. The T315I mutation confers resistance to all approved ATP-competitive TKIs except ponatinib (PON) and is associated with significantly worse clinical outcomes. PON use, howeve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5070f573-12c7-53a0-80a9-95c612569dd0
DOI: 10.1182/blood-2020-139677

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 TrialDOI 10.1182/blood-2020-139677Read

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read

Asciminib as a third line option in chronic myeloid leukemia.Semantic proximity Read

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Semantic proximity Read

Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.Semantic proximity Read

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.Semantic proximity Read

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read

[Recent advances in the treatment of chronic myeloid leukemia].Semantic proximity Read

Asciminib in chronic myeloid leukemia.Semantic proximity Read

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Semantic proximity Read